CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
2 of 10
|
1
|
NAMES
OF REPORTING PERSONS
TPG
GP A, LLC
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a) ☐
(b)
☐
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS (see instructions)
OO
(See Item 3)
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
Delaware
|
NUMBER
OF SHARES
|
7
|
SOLE
VOTING POWER
- 0 -
|
BENEFICIALLY
OWNED BY
|
8
|
SHARED
VOTING POWER
16,213,367
(See Items 3, 4 and 5)
|
EACH
REPORTING PERSON
|
9
|
SOLE
DISPOSITIVE POWER
- 0 -
|
WITH
|
10
|
SHARED
DISPOSITIVE POWER
16,213,367
(See Items 3, 4 and 5)
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,213,367
(See Items 3, 4 and 5)
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.9%
(See Item 5)*
|
14
|
TYPE
OF REPORTING PERSON
OO
|
|
|
*The
calculation is based on a total of 149,371,355 Class A Shares (as defined herein) outstanding as of October 29, 2021, as reported
in the Quarterly Report on Form 10-Q filed by the Issuer (as defined herein) with the Securities and Exchange Commission (the “Commission”)
on November 8, 2021.
|
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
3 of 10
|
1
|
NAMES
OF REPORTING PERSONS
David
Bonderman
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a)
☐
(b)
☐
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS (see instructions)
OO
(See Item 3)
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States of America
|
NUMBER
OF SHARES
|
7
|
SOLE
VOTING POWER
-0-
|
BENEFICIALLY
OWNED BY
|
8
|
SHARED
VOTING POWER
16,213,367
(See Items 3, 4 and 5)
|
EACH
REPORTING PERSON
|
9
|
SOLE
DISPOSITIVE POWER
-0-
|
WITH
|
10
|
SHARED
DISPOSITIVE POWER
16,213,367
(See Items 3, 4 and 5)
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,213,367
(See Items 3, 4 and 5)
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.9%
(See Item 5)*
|
14
|
TYPE
OF REPORTING PERSON
IN
|
|
|
|
|
|
|
*The
calculation is based on a total of 149,371,355 Class A Shares outstanding as of October 29, 2021, as reported in the Quarterly Report
on Form 10-Q filed by the Issuer with the Commission on November 8, 2021.
|
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
4 of 10
|
1
|
NAMES
OF REPORTING PERSONS
James G. Coulter
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a)
☐
(b)
☐
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS (see instructions)
OO
(See Item 3)
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States of America
|
NUMBER
OF SHARES
|
7
|
SOLE
VOTING POWER
-0-
|
BENEFICIALLY
OWNED BY
|
8
|
SHARED
VOTING POWER
16,213,367
(See Items 3, 4 and 5)
|
EACH
REPORTING PERSON
|
9
|
SOLE
DISPOSITIVE POWER
-0-
|
WITH
|
10
|
SHARED
DISPOSITIVE POWER
16,213,367
(See Items 3, 4 and 5)
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,213,367
(See Items 3, 4 and 5)
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.9%
(See Item 5)*
|
14
|
TYPE
OF REPORTING PERSON
IN
|
*The
calculation is based on a total of 149,371,355 Class A Shares outstanding as of October 29, 2021, as reported in the Quarterly Report
on Form 10-Q filed by the Issuer with the Commission on November 8, 2021.
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
5 of 10
|
1
|
NAMES
OF REPORTING PERSONS
Jon Winkelried
|
2
|
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
(a)
☐
(b)
☐
|
3
|
SEC
USE ONLY
|
4
|
SOURCE
OF FUNDS (see instructions)
OO
(See Item 3)
|
5
|
CHECK
BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
6
|
CITIZENSHIP
OR PLACE OF ORGANIZATION
United
States of America
|
NUMBER
OF SHARES
|
7
|
SOLE
VOTING POWER
-0-
|
BENEFICIALLY
OWNED BY
|
8
|
SHARED
VOTING POWER
16,213,367
(See Items 3, 4 and 5)
|
EACH
REPORTING PERSON
|
9
|
SOLE
DISPOSITIVE POWER
-0-
|
WITH
|
10
|
SHARED
DISPOSITIVE POWER
16,213,367
(See Items 3, 4 and 5)
|
11
|
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
16,213,367
(See Items 3, 4 and 5)
|
12
|
CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions) ☐
|
13
|
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.9%
(See Item 5)*
|
14
|
TYPE
OF REPORTING PERSON
IN
|
*The
calculation is based on a total of 149,371,355 Class A Shares outstanding as of October 29, 2021, as reported in the Quarterly Report
on Form 10-Q filed by the Issuer with the Commission on November 8, 2021.
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
6 of 10
|
This
Amendment No. 2 (the “Amendment”) amends and supplements the Schedule 13D filed by the Reporting Persons on May 14,
2018, as amended and supplemented by Amendment No. 1 filed on July 10, 2019 (as so amended, the “Original Schedule 13D”
and, as amended and supplemented by this Amendment, the “Schedule 13D”), with respect to the Class A Shares. Capitalized
terms used in this Amendment and not otherwise defined shall have the same meanings ascribed to them in the Original Schedule 13D.
Item
2. Identity and Background.
This
Amendment amends and restates Item 2 of the Original Schedule 13D in its entirety as set forth below:
“This
Schedule 13D is being filed jointly on behalf of TPG GP A, LLC, a Delaware limited liability company (“TPG GP A”),
David Bonderman, James G. Coulter and Jon Winkelried (each a “Reporting Person” and collectively, the “Reporting
Persons”). The business address of each Reporting Person is c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, Texas
76102.
TPG
GP A is the managing member of TPG Group Holdings (SBS) Advisors, LLC, a Delaware limited liability company, which is the general partner
of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which holds 100% of the shares of Class B common stock (which represents
a majority of the combined voting power of the common stock) of TPG Inc., a Delaware corporation (“TPG”), which is
the controlling shareholder of TPG GPCo, Inc., a Delaware corporation, which is the managing member of TPG Holdings I-A, LLC, a Delaware
limited liability company, and (ii) the sole shareholder of TPG Holdings III-A, Inc., a Cayman corporation. TPG Holdings I-A, LLC is
the general partner of TPG Operating Group I, L.P., a Delaware limited partnership, which is the sole member of TPG GenPar VII Advisors,
LLC, a Delaware limited liability company, which is the general partner of TPG GenPar VII, L.P., a Delaware limited partnership, which
is the general partner of TPG Improv Holdings, L.P., a Delaware limited partnership (“TPG Improv”), which directly
holds 12,328,767 Class A Shares. TPG Holdings III-A, Inc. is the general partner of TPG Holdings III-A, L.P., a Cayman limited partnership,
which is the general partner of TPG Operating Group III, L.P., a Delaware limited partnership, which is general partner of TPG PEP GenPar
Advisors, L.P., a Delaware limited partnership, which is the general partner of TPG PEP GenPar Governance, L.P., a Delaware limited partnership,
which is the general partner of each of (i) TPG Public Equity Partners, L.P., a Delaware limited partnership, which directly holds 430,412
Class A Shares, and (ii) TPG Public Equity Partners Master Fund, L.P., a Cayman Islands limited partnership (together with TPG Public
Equity Partners, L.P., the “TPEP Funds”), which directly holds 3,454,188 Class A Shares.
Because
of the relationship of TPG GP A to TPG Improv and the TPEP Funds, TPG GP A may be deemed to beneficially own the securities reported
herein. TPG GP A is owned by entities owned by Messrs. Bonderman, Coulter and Winkelried. Because of the relationship of Messrs. Bonderman,
Coulter and Winkelried to TPG GP A, each of Messrs. Bonderman, Coulter and Winkelried may be deemed to beneficially own the securities
reported herein. Messrs. Bonderman, Coulter and Winkelried disclaim beneficial ownership of the securities reported herein except to
the extent of their pecuniary interest therein.
In
connection with TPG’s initial public offering, TPG engaged in certain transactions as part of a corporate reorganization. As a
result of the reorganization, TPG GP A replaced TPG Group Holdings (SBS) Advisors, Inc. as the managing member of TPG Group Holdings
(SBS) Advisors, LLC and thus is replacing TPG Group Holdings (SBS) Advisors, Inc. as a Reporting Person on this Schedule 13D.
The
principal business of TPG GP A is serving as the sole ultimate general partner, managing member or similar entity of related entities
engaged in making or recommending investments in securities of public and private companies.
The
present principal occupation of Mr. Bonderman is Non-Executive Chairman and Director of TPG and officer, director and/or manager of other
affiliated entities.
The
present principal occupation of Mr. Coulter is Executive Chairman and Director of TPG and officer, director and/or manager of other affiliated
entities.
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
7 of 10
|
The
present principal occupation of Mr. Winkelried is Chief Executive Officer and Director of TPG and officer, director and/or manager of
other affiliated entities.
The
name, residence or business address and present principal occupation or employment of each director, executive officer and controlling
person of TPG GP A are listed on Schedule I hereto.
Each
of Messrs. Bonderman, Coulter, Winkelried and the individuals referred to on Schedule I hereto is a United States citizen.
The
agreement among the Reporting Persons relating to the joint filing of this Schedule 13D is attached as Exhibit 1 hereto.
During
the last five years, none of the Reporting Persons nor, to the knowledge of the Reporting Persons, without independent verification,
any of the persons listed on Schedule I hereto (i) has been convicted in any criminal proceeding (excluding traffic violations or similar
misdemeanors) or (ii) was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result
of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating
activities subject to, federal or state securities laws or finding any violation with respect to such laws.”
Item
5. Interest in Securities of the Issuer.
This
Amendment amends and restates the second paragraph of Item 5 of the Original Schedule 13D in its entirety as set forth below:
“(a)-(b)
The following sentence is based on a total of 149,371,355 Class A Shares outstanding as of October 29, 2021, as reported in the Quarterly
Report on Form 10-Q filed by the Issuer with the Commission on November 8, 2021. Pursuant to Rule 13d-3 under the Act, the Reporting
Persons may be deemed to beneficially own 16,213,367 Class A Shares, which constitutes approximately 10.9% of the outstanding Class A
Shares.”
Item
7. Material to Be Filed as Exhibits.
This
Amendment amends and restates Item 1 listed in Item 7 of the Original Schedule 13D in its entirety as set forth below:
|
“1.
|
Agreement
of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII,
Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David
Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022
(incorporated herein by reference to Exhibit 1 to Amendment No. 4 to Schedule 13D filed by
TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022
with respect to the shares of common stock of Allogene Therapeutics, Inc.).”
|
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
8 of 10
|
SIGNATURE
After
reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete
and correct.
Dated:
January 18, 2022
|
TPG
GP A, LLC
|
|
|
|
|
|
By:
|
/s/
Bradford Berenson
|
|
Name:
|
Bradford
Berenson
|
|
Title:
|
General
Counsel
|
|
|
|
|
|
David
Bonderman
|
|
|
|
|
|
By:
|
/s/
Gerald Neugebauer
|
|
Name:
|
Gerald
Neugebauer on behalf of David Bonderman (1)
|
|
|
|
|
|
James
G. Coulter
|
|
|
|
|
|
By:
|
/s/
Gerald Neugebauer
|
|
Name:
|
Gerald
Neugebauer on behalf of James G. Coulter (2)
|
|
|
|
|
|
|
|
Jon
Winkelried
|
|
|
|
|
|
By:
|
/s/
Gerald Neugebauer
|
|
Name:
|
Gerald
Neugebauer on behalf of Jon Winkelried (3)
|
(1)
Gerald Neugebauer is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated February 26, 2020,
which was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Bonderman on March 6, 2020 (SEC File No. 001-38156).
(2)
Gerald Neugebauer is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated February 26, 2020, which
was previously filed with the Commission as an exhibit to a Form 4 filed by Mr. Coulter on March 6, 2020 (SEC File No. 001-38156).
(3)
Gerald Neugebauer is signing on behalf of Mr. Winkelried pursuant to an authorization and designation letter dated October 20, 2020,
which was previously filed with the Commission as an exhibit to a Form 3 filed by Mr. Winkelried on October 22, 2020 (SEC File No. 001-39651).
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
9 of 10
|
SCHEDULE
I
Information
with Respect to Executive Officers of TPG GP A, LLC. All addresses are c/o TPG Inc., 301 Commerce Street, Suite 3300, Fort Worth, Texas
76102.
Name
|
|
Title
|
James
G. Coulter
|
|
Executive
Chairman
|
Jon
Winkelried
|
|
Chief
Executive Officer
|
Jack
Weingart
|
|
Chief
Financial Officer
|
Ken
Murphy
|
|
Chief
Operating Officer
|
Anilu
Vazquez-Ubarri
|
|
Chief
Human Resources Officer
|
Bradford
Berenson
|
|
General
Counsel
|
Joann
Harris
|
|
Chief
Compliance Officer
|
CUSIP
No. 03168L105
|
SCHEDULE
13D
|
Page
10 of 10
|
Exhibit
Index
-
Agreement of Joint Filing by TPG Group Holdings (SBS) Advisors, Inc., TPG GP A, LLC, TPG Advisors VII, Inc., TPG Advisors VI, Inc., TPG Advisors VI-AIV, Inc., TPG Asia Advisors VI, Inc., David Bonderman, James G. Coulter, Jon Winkelried and Karl Peterson dated as of January 18, 2022 (incorporated herein by reference to Exhibit 1 to Amendment No. 4 to Schedule 13D filed by TPG GP A, LLC, David Bonderman, James G. Coulter and Jon Winkelried on January 18, 2022 with respect to the shares of common stock of Allogene Therapeutics, Inc.).
-
Share Purchase Agreement dated as of October 17, 2017 by and among Amneal Holdings, LLC and the purchasers set forth in Schedule A thereto (incorporated by reference to Exhibit 2 to Schedule 13D filed by the Reporting Persons on May 14, 2018 with respect to the Issuer).
-
Amendment No. 1 to Share Purchase Agreement dated as of May 3, 2018 by and between TPG Improv Holdings, L.P. and Amneal Holdings, LLC (incorporated by reference to Exhibit 3 to Schedule 13D filed by the Reporting Persons on May 14, 2018 with respect to the Issuer).
-
Letter Agreement dated as of November 21, 2017 by and among Amneal Holdings, LLC, Amneal Pharmaceuticals, Inc. and TPG Improv Holdings, L.P. (incorporated by reference to Exhibit 2.4 to the Issuer’s Registration Statement on Form S-1 filed with the Commission on May 7, 2018).
-
Form of Restated Certificate Of Incorporation Amneal Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 to the Issuer’s Registration Statement on Form S-1 filed with the Commission on May 7, 2018).